Kerri E. Rieger

Kerri E. Rieger

Auto-generated profile, based on publicly available information

Kerri E. Rieger

Department of Dermatology Stanford University School of Medicine Stanford California USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2019 in JCI Insight
Verified
Journal Article
Open access
PDF file
SEShaundra Eichstadt
Shaundra Eichstadt
MBMelissa Barriga
Melissa Barriga
APAnusha Ponakala
Anusha Ponakala
CTClaudia Teng
Claudia Teng
NNNgon T. Nguyen
Ngon T. Nguyen
JTJean Y. Tang
Jean Y. Tang
BACKGROUND: Recessive dystrophic epidermolysis bullosa (RDEB) patients have mutations in the COL7A1 gene and thus lack functional type VII collagen (C7) protein; they have marked skin fragility and blistering. This single-center phase 1/2a open-label study evaluated the long-term efficacy, safety, and patient-reported outcomes in RDEB patients treated with gene-corrected autologous cell therapy. METHODS: Autologous keratinocytes were isolated from participant skin biopsies. Epidermal sheets were prepared from cells transduced with a retrovirus carrying the full-length human COL7A1 gene. These gene-corrected autologous epidermal sheets measured 5 × 7 cm (35 cm 2 ) and were transplanted onto 6 wound sites in each of 7 adult participants ( n = 42 sites total) from 2013 to 2017. Participants were followed for 2 to 5 years. RESULTS: No participants experienced any serious related adverse events. Wound healing of 50% or greater by Investigator Global Assessment was present in 95% (36 of 38) of treated wounds versus 0% (0 of 6) of untreated control wounds at 6 months ( P < 0.0001). At year 1, 68% (26 of 38) of treated wounds had 50% or greater healing compared with 17% (1 of 6) of control wounds ( P = 0.025). At year 2, 71% (27 of 38) of treated wounds had 50% or greater healing compared with 17% (1 of 6) of control wounds ( P = 0.019). CONCLUSION: C7 expression persisted up to 2 years after treatment in 2 participants. Treated wounds with 50% or greater healing demonstrated improvement in patient-reported pain, itch, and wound durability. This study provides additional data to support the clinically meaningful benefit of treating chronic RDEB wounds with ex vivo, C7 gene–corrected autologous cell therapy. This approach was safe and promoted wound healing that was associated with improved patient-reported outcomes. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT01263379. FUNDING: Epidermolysis Bullosa Research Partnership, Epidermolysis Bullosa Medical Research Foundation, NIH R01 AR055914, Office of Research and Development at the Palo Alto Veteran’s Affairs Medical Center, and the Dermatology Foundation.

23 July 2020 in Journal of Cutaneous Pathology
Verified
Journal Article
Closed access
PDF file
SRShyam Raghavan
Shyam Raghavan
JWJennifer Y. Wang
Jennifer Y. Wang
SKShirley Kwok
Shirley Kwok
KRKerri E. Rieger
Kerri E. Rieger
RNRoberto A. Novoa
Roberto A. Novoa
RBRyanne A. Brown
Ryanne A. Brown

8 October 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
CYCatherine D. Yao
Catherine D. Yao
DHDaniel Haensel
Daniel Haensel
SGSadhana Gaddam
Sadhana Gaddam
TPTiffany Patel
Tiffany Patel
SAScott Atwood
Scott Atwood
AOAnthony E. Oro
Anthony E. Oro
Tumor heterogeneity and lack of knowledge about resistant cell states remain a barrier to targeted cancer therapies. Basal cell carcinomas (BCCs) depend on Hedgehog (Hh)/Gli signaling, but can develop mechanisms of Smoothened (SMO) inhibitor resistance. We previously identified a nuclear myocardin-related transcription factor (nMRTF) resistance pathway that amplifies noncanonical Gli1 activity, but characteristics and drivers of the nMRTF cell state remain unknown. Here, we use single cell RNA-sequencing of patient tumors to identify three prognostic surface markers (LYPD3, TACSTD2, and LY6D) which correlate with nMRTF and resistance to SMO inhibitors. The nMRTF cell state resembles transit-amplifying cells of the hair follicle matrix, with AP-1 and TGFß cooperativity driving nMRTF activation. JNK/AP-1 signaling commissions chromatin accessibility and Smad3 DNA binding leading to a transcriptional program of RhoGEFs that facilitate nMRTF activity. Importantly, small molecule AP-1 inhibitors selectively target LYPD3+/TACSTD2+/LY6D+ nMRTF human BCCs ex vivo, opening an avenue for improving combinatorial therapies.

12 April 2024 in Science Advances
Verified
Journal Article
Open access
YWYonatan Winetraub
Yonatan Winetraub
AVAidan Van Vleck
Aidan Van Vleck
EYEdwin Yuan
Edwin Yuan
ITItamar Terem
Itamar Terem
JZJinjing Zhao
Jinjing Zhao
AZAdam de la Zerda
Adam de la Zerda
Histological hematoxylin and eosin–stained (H&E) tissue sections are used as the gold standard for pathologic detection of cancer, tumor margin detection, and disease diagnosis. Producing H&E sections, however, is invasive and time-consuming. While deep learning has shown promise in virtual staining of unstained tissue slides, true virtual biopsy requires staining of images taken from intact tissue. In this work, we developed a micron-accuracy coregistration method [micro-registered optical coherence tomography (OCT)] that can take a two-dimensional (2D) H&E slide and find the exact corresponding section in a 3D OCT image taken from the original fresh tissue. We trained a conditional generative adversarial network using the paired dataset and showed high-fidelity conversion of noninvasive OCT images to virtually stained H&E slices in both 2D and 3D. Applying these trained neural networks to in vivo OCT images should enable physicians to readily incorporate OCT imaging into their clinical practice, reducing the number of unnecessary biopsy procedures.

24 September 2020 in American Journal of Surgical Pathology
Verified
Journal Article
Closed access
JWJennifer Y. Wang
Jennifer Y. Wang
KHKelsey E. Hirotsu
Kelsey E. Hirotsu
TNTatiana M. Ba Neal
Tatiana M. Ba Neal
SRShyam S. Raghavan
Shyam S. Raghavan
BKBernice Y. Kwong
Bernice Y. Kwong
KRKerri E. Rieger
Kerri E. Rieger
Rash is one of the most common adverse events observed with mogamulizumab, an anti-C-C chemokine receptor 4 monoclonal antibody approved for previously treated mycosis fungoides (MF) and Sezary syndrome (SS). Given the nonspecific clinical presentations of this rash, histopathologic distinction from MF/SS is critical for informing clinical management. We performed a comprehensive characterization of the histopathologic findings in mogamulizumab-associated rash (MAR) with the integration of high-throughput sequencing of T-cell receptor (TCR) genes. Fifty-two biopsy specimens from 19 patients were evaluated retrospectively. Three major histologic reaction patterns were identified: spongiotic/psoriasiform dermatitis (33/52), interface dermatitis (11/52), and granulomatous dermatitis (8/52). Almost half of the specimens (21/52) showed at least 2 of these reaction patterns concurrently. Dermal eosinophils were not a consistent feature, being present in only half (27/52) of specimens and prominent in only 3. Features mimicking MF/SS, including lymphocyte exocytosis, lamellar fibroplasia, and adnexal involvement, were commonly seen but tended to be focal and mild. In 38/43 specimens with available immunohistochemistry, intraepidermal lymphocytes demonstrated a CD4:CD8 ratio ≤1 : 1. Low background levels of the patient’s previously identified MF/SS-associated TCR sequence(s) were demonstrated in 20/46 specimens analyzed by high-throughput sequencing of TCR. We conclude that MAR may demonstrate diverse histologic features. Findings that may distinguish MAR from MF/SS include the inverted or normalized CD4:CD8 ratio within intraepidermal lymphocytes and demonstration of absent or nondominant levels of disease-associated TCR sequences. Correlation with the clinical findings and immunohistochemical and molecular characterization of the patient’s MF/SS before mogamulizumab, when possible, may facilitate recognition of MAR.

2 May 2023 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
KTKim Thrane
Kim Thrane
MWMårten C.G. Winge
Mårten C.G. Winge
HWHongyu Wang
Hongyu Wang
LCLarry Chen
Larry Chen
MGMargaret G. Guo
Margaret G. Guo
AJAndrew L. Ji
Andrew L. Ji